Vera Therapeutics, Inc.
Clinical trials sponsored by Vera Therapeutics, Inc., explained in plain language.
-
New monthly shot could tame kidney disease
Disease control OngoingThis study tests a drug called atacicept in 90 adults with IgA nephropathy, a kidney disease. Participants receive the drug every four weeks to see if it lowers harmful antibodies linked to the condition. The goal is to control the disease and prevent kidney damage.
Phase: PHASE2 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control
Last updated Jun 23, 2026 11:57 UTC
-
New drug could slow kidney damage in IgA nephropathy patients
Disease control OngoingThis phase 3 study tests a drug called atacicept in 376 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if atacicept can reduce protein in the urine and slow the loss of kidney function compared to a placebo. Participants must hav…
Phase: PHASE3 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control
Last updated Jun 18, 2026 11:47 UTC